Rockwell Medical Technologies (NASDAQ: RMTI) reported Q2 EPS of ($0.05), $0.05 better than the analyst estimate of ($0.10). Revenue for the quarter came in at $12.9 million versus the consensus estimate of $11.84 million.

"As expected, we had another solid quarter," stated Robert L. Chioini, Chairman and CEO of Rockwell. "Our focus and effort the last five months has been on performing the necessary work to launch Triferic commercially, as well as Calcitriol. Since our FDA approval of Triferic, interest from the clinical community in gaining access to the drug has been strong across large and small dialysis organizations. Short-term pilot evaluations are being coordinated among some of the larger groups to establish internal protocol, prior to clinic-wide use. We anticipate these pilot studies will begin in the next few weeks. Once internal protocols are established and working satisfactorily, we expect to see broad-based clinical adoption of Triferic."

For earnings history and earnings-related data on Rockwell Medical Technologies (RMTI) click here.